Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 20Active not recruiting 9Terminated 8Recruiting 8Withdrawn 3Unknown 3Approved for marketing 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 16Recurrence 3Neoplasms, Plasma Cell 2Renal Insufficiency 1Paraproteinemias 1Neoplasms by Histologic Type 1Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Hypoxia 1High Grade Squamous Intra-epithelial Lesion (HSIL) 1Hematologic Diseases 1Disease Progression 1Blood Protein Disorders 1Amyloidosis 1

Interventions

Cyclophosphamide 17fludarabine 13Dexamethasone 12Cisplatin 11Rituximab 10Gemcitabine 9Paclitaxel 7Lenalidomide 7Decitabine 7Cytarabine 7Bendamustine Hydrochloride 7fludarabine phosphate 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Etoposide 6Carboplatin 6Bortezomib 6Radiotherapy 5Injections 5Azacitidine 5camrelizumab 4apatinib 4Valproic Acid 4Thalidomide 4Procarbazine 4Oxaliplatin 4Drug Therapy 4Antilymphocyte Serum 4tislelizumab 3pomalidomide 3liposomal doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Recurrence × pomalidomide × Clear all
NCT05236621 2022-02-11

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Qilu Pharmaceutical Co., Ltd.

Phase 3 Unknown
85 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Sun Yat-sen University

Phase 1/2 Unknown
56 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT03601624 2018-11-14

MM-POM-2018

Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

Phase 2 Unknown
18 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡